16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social...read more
Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Elevation Oncology is developing monoclonal antibody...read more
Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $100 million by offering 6.3 million shares at a price range of...read more
Elevation Oncology, a Phase 2 biotech developing monoclonal antibodies for genetically-defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Elevation Oncology is developing monoclonal antibody...read more
US IPO Weekly Recap: Doximity pops more than 100% in a 16 IPO week
16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social...read more
Oncology biotech Elevation Oncology prices IPO at $16 midpoint
Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Elevation Oncology is developing monoclonal antibody...read more
Oncology biotech Elevation Oncology sets terms for $100 million IPO
Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $100 million by offering 6.3 million shares at a price range of...read more
Phase 2 oncology biotech Elevation Oncology files for a $100 million IPO
Elevation Oncology, a Phase 2 biotech developing monoclonal antibodies for genetically-defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Elevation Oncology is developing monoclonal antibody...read more